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bjectives The purpose of this study was to evaluate the safety of dual antiplatelet therapy in pa-
ients in whom long-term anticoagulation (AC) with warfarin is recommended.
ackground The optimal antithrombotic strategy after percutaneous coronary intervention (PCI) for
atients receiving AC is unclear.
ethods Consecutive patients who underwent stent implantation and were discharged on triple
herapy (deﬁned as the combination of aspirin and thienopyridines and AC) were analyzed.
esults Of the 127 patients with 224 lesions, 86.6% were men, with a mean age of 69.9  8.8
ears. Drug-eluting stents (DES) were positioned in 71 (55.9%), and bare-metal stents (BMS) were
ositioned in 56 (44.1%) patients. Atrial ﬁbrillation (AF) was the main indication (59.1%) for AC treat-
ent. The mean triple therapy duration was 5.6  4.6 months, and clinical follow-up was 21.0 
9.8 months. During the triple therapy period, 6 patients (4.7%) developed major bleeding compli-
ations; 67% occurred within the ﬁrst month. No signiﬁcant differences between DES and BMS were
bserved in the incidence of major (5.6% vs. 3.6%, respectively, p  1.0) and minor (1.4% vs. 3.6%,
espectively, p  0.57) bleeding and mortality (5.6% vs. 1.8%, respectively, p  0.39). A signiﬁcant
ifference was observed in favor of DES in target vessel revascularization (14.1% vs. 26.8%, p 
.041).
onclusions While receiving triple therapy, major bleeding occurred in 4.7% of patients; one-half of
he events were lethal, and most occurred within the ﬁrst month. (J Am Coll Cardiol Intv 2008;1:
6–61) © 2008 by the American College of Cardiology Foundation
rom the San Raffaele Scientific Institute and Emo Centro Cuore Columbus, Milan, Italy.anuscript received September 12, 2007; revised manuscript received October 31, 2007, accepted November 20, 2007.
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Dual Antiplatelet Therapy and Anticoagulation After PCI
57he optimal antiplatelet therapy after percutaneous coronary
ntervention (PCI) with stent implantation consists of a com-
ination of aspirin and ticlopidine or clopidogrel for the
revention of stent thrombosis (1–4). At the present time, it is
till unclear which antithrombotic strategy is optimal for
atients in whom long-term anticoagulation (AC) with war-
arin is recommended. The risk of bleeding in patients already
See page 62
n AC is increased with the addition of dual antiplatelet
herapy, although at the same time withholding antiplatelet
herapy augments the risk of stent thrombosis. Further-
ore, a temporary discontinuation of AC is associated with
higher risk of thromboembolism (5), and current liberal
se of drug-eluting stents (DES) might increase the overall
isk of stent thrombosis. Therefore, the aim of this study
as to evaluate the safety at short- and mid-term clinical
ollow-up of dual antiplatelet therapy in patients in whom
ong-term AC with warfarin is recommended.
ethods
ll consecutive patients who underwent PCI in our insti-
utions (San Raffaele Hospital and Emo Centro Cuore
olumbus, Milan, Italy) from February 1999 to December
006 and were successively discharged on a triple therapy
ith aspirin and thienopyridines (ticlopidine or clopidogrel)
nd oral anticoagulant (warfarin) were analyzed.
All the patients were pretreated with thienopyridines and
spirin before the PCI procedure as follows: 100 mg aspirin
nd 250 mg ticlopidine twice daily, 75 mg of clopidogrel for
t least 5 days, or a loading dose of 300 mg of clopidogrel
efore the procedure (if the pretreatment regimen was not
ollowed or in the case of emergency PCI). Regarding the
ral AC therapy, all the patients who underwent PCI had
iscontinued warfarin therapy for at least 3 days before
ospital admission and were treated with weight-adjusted
oses of low molecular weight heparin until 12 h before the
ndex procedure (6). The maximum international normalized
atio (INR) allowed to start the procedure, according to our
nstitution practice, was 1.5. If an emergency PCI was to be
one or INR remained 1.5, a radial access was preferable.
Coronary angioplasty and DES implantation were performed
ccording to our practice of fully covering the diseased segment
7–9). At the start of the procedure, a bolus of unfractionated
eparin was administered at 100 IU/kg to achieve an activated
lotting time 250 s. Glycoprotein IIb/IIIa inhibitors were
dministered at the discretion of the operator.
Warfarin therapy was restarted at the maintenance dose
ithin 24 h after the procedure, and the patients remained
n low molecular weight heparin treatment until an optimal
NR for each pathology was achieved. The control of INR
alues was left to the referral cardiologist. To our best knowl- gdge, the cardiologists advise periodic control of INR in order
o dose warfarin appropriately. During the follow-up period,
he patients were asked whether they followed their cardiolo-
ists’ advice and whether their INR was maintained optimally.
e do not have any evidence that there were any patients with
NR out of the desired range.
Dual antiplatelet therapy (aspirin 100 mg daily and
lopidogrel 75 mg or ticlopidine 250 mg twice daily) was
dministrated in all patients for at least 1 month after
are-metal stent (BMS) and 6 to 12 months after DES
mplantation. All patients were advised to maintain aspirin
100 mg daily) lifelong.
Clinical follow-up was scheduled for all patients at 1, 6, and
2 months by office visit or direct telephone call. Detailed
uestions on general health status, major adverse cardiac and
erebrovascular events (MACCE), bleeding complications, re-
urrent hospital admissions, and
ctual pharmacological treat-
ent (including the length of
he triple therapy and the reason
or and date of discontinuation
f any of the 3 drugs) were asked
o all the monitored patients.
eﬁnitions. The events analyzed
uring hospital stay and at clin-
cal follow-up were MACCE and
leeding complications.
The MACCE were defined as
he occurrence, during hospital
tay and at clinical follow-up, of
ny of the following: all-cause
eath, myocardial infarction
MI), target lesion revasculariza-
ion, target vessel revasculariza-
ion (TVR), cerebrovascular
vents, and stent thrombosis.
Deaths were classified as cardiac,
erebral, or not from cardio-cerebral
auses. Death of unknown cause was adjudicated as cardiac.
An MI was defined as a 2 times increase of the upper
imit of normal serum creatine kinase in conjunction with
ositive creatine kinase-myocardial band isoenzyme (10).
Any revascularization performed on the treated segment was
efined as target lesion revascularization, whereas any reinter-
ention performed on the treated vessel was defined as TVR.
The stent thrombosis definition used in this study is
onsistent with the newest consensus of the Academic
esearch Consortium based on the trilevel certainty classi-
cation (definite, probable, and possible) and timing (acute,
ubacute, late, and very late) (11).
Cerebrovascular events included stroke (ischemic or hemor-
hagic), cerebral hemorrhage, transient ischemic attacks, and
eversible ischemic neurological deficits adjudicated by a neurolo-
Abbreviations
and Acronyms
AC  anticoagulation
AF  atrial fibrillation
BMS  bare-metal stent(s)
INR  international
normalized ratio
MACCE  major adverse
cardiac and cerebrovascular
events
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationist and confirmed by computed tomography scanning (12).
m
o
r
r
f
o
u
c
S
s
v
w
p
R
B
w
(
y
1
c
(
t
a
p
p
i
d
D
e
(
w
5
v
p
c
b
r
1
H
i
I
t
h
t
p
m
2
r
a
t
c
3
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 1 , 2 0 0 8
F E B R U A R Y 2 0 0 8 : 5 6 – 6 1
Rogacka et al.
Dual Antiplatelet Therapy and Anticoagulation After PCI
58Bleeding complications were divided into minor and
ajor (5). Major bleeding was defined as the cumulative
ccurrence of intracranial or intraocular bleeding, hemor-
hage at the vascular access site requiring intervention, a
eduction in hemoglobin levels of at least 5 g/dl, reoperation
or bleeding or transfusion of a blood product (at least 2 U),
r bleeding causing substantial hypotension requiring the
se of inotropic agents. All other bleeding events were
onsidered minor (e.g., epistaxis, blood traces in the stool).
tatistical analysis. Statistical analysis was performed with SPSS
oftware version 10.1 (SPSS Inc., Chicago, Illinois). Continuous
ariables are reported as the mean value SD and are compared
ith the Student t test. Categorical variables are presented as
ercentages and are compared with the chi-square test.
esults
aseline clinical characteristics are summarized in Table 1.
One hundred twenty-seven patients (with 224 lesions)
ere included in the analysis: 30 (24.0%) were diabetic, 94
74.0%) had multivessel disease, mean age was 69.9  8.8
ears, and left ventricular ejection fraction was 44.9 
3.2%. There were no significant differences in the baseline
linical characteristics between the DES and BMS group
Table 1), except for unstable presentation of the patients in
he BMS group (32.1% vs. 15.5% in DES, p  0.04).
Table 1. Baseline Characteristics of the Study Population
Total
(n  127)
DES
(n  71)
BMS
(n  56)
p
Value
Age, yrs 69.9  8.8 68.8  8.6 70.2  7.6 0.61
Male gender, n (%) 110 (86.6) 61 (85.9) 49 (87.5) 1.0
Hypertension, n (%) 85 (66.9) 50 (70.4) 35 (62.5) 0.45
Diabetes, n (%) 30 (24.0) 16 (22.5) 14 (25) 0.83
Noninsulin-dependent
diabetes, n (%)
26 (86.7) 12 (75.0) 14 (100.0)
Insulin-dependent
diabetes, n (%)
4 (13.3) 4 (25.0) 0 (0.0)
Hyperlipidemia, n (%) 59 (46.4) 38 (53.5) 21 (37.5) 0.05
Current smoker, n (%) 8 (6.3) 6 (8.5) 2 (3.6) 0.46
Family history of CAD, n (%) 45 (35.4) 23 (32.4) 22 (39.3) 0.46
Previous MI, n (%) 68 (53.5) 38 (53.5) 30 (53.6) 1.0
Previous PCI, n (%) 48 (37.8) 28 (39.4) 20 (35.7) 0.71
Previous CABG, n (%) 39 (30.7) 23 (32.4) 16 (28.6) 0.70
LVEF, % 44.9  13.2 44.6  12.7 47.4  15.5 0.24
Stable angina, n (%) 60 (47.2) 34 (47.9) 26 (46.4) 0.04
Unstable angina, n (%) 29 (22.8) 11 (15.5) 18 (32.1) 0.04
STEMI, n (%) 4 (3.1) 1 (1.4) 3 (5.4) 0.32
CHADS2 risk score for
AF patients
1.79  1.23 1.96  1.21 1.59  1.21 0.32
AF atrial fibrillation; BMS bare-metal stents; CABG coronary artery bypass grafting; CAD
coronary artery disease; CHADS2  Congestive heart failure, Hypertension, Age 75 years,
Diabetes, prior transient ischemic attack, or Stroke-2; DES  drug-eluting stents; LVEF  left
ventricular ejection fraction; MImyocardial infarction; PCI percutaneous coronary interven-tion; STEMI ST-segment elevation myocardial infarction.Twenty-nine (22.8%) patients presented with unstable
ngina; 4 (3.1%) had ST-segment elevation MI requiring a
rimary PCI (1 in the DES group vs. 3 in the BMS group,
 0.32). In the DES group, the number of stents
mplanted and total stent length were larger and vessel
iameter smaller (Table 2). In most (55.9%) of the patients,
ES were implanted with a greater prevalence of sirolimus-
luting stents (SES) over paclitaxel-eluting stents (PES)
59.2% vs. 35.2%).
The most frequent indication for long-term AC therapy
ith warfarin was atrial fibrillation (AF) (75 patients,
9.1%). The other indications (Table 3) included left
entricular mural thrombus, prosthetic valves, history of
ulmonary embolism or deep vein thrombosis, evidence of
oronary or peripheral aneurysm, or complicated peripheral
ypass grafting (defined as “Other” in Table 3). The average
isk of thromboembolic events in the subgroup with AF was
.79  1.23 according to the Congestive heart failure,
ypertension, Age 75 years, Diabetes, prior transient
schemic attack, or Stroke-2 points (CHADS2) score (5).
n-hospital and long-term MACCE and bleeding complica-
ions. During hospital stay, no patient died and 7 (5.5%)
ad periprocedural MI (4.2% in the DES group vs. 7.1% in
he BMS group, p  0.70). No groin hematomas or other
eriprocedural bleeding complications were observed. The
ean clinical follow-up was 21.0  19.8 months (25.5 
4.0 in the BMS group vs. 16.9  14.0 in the DES group,
espectively; p  0.021). Patients were on concomitant dual
ntiplatelet and AC therapy for 5.6  4.6 months. This
ime period was significantly prolonged in the DES group as
ompared with the BMS group (7.7 3.6 months vs. 3.1
.6 months; p  0.001).
Table 2. Procedural Characteristics
Total DES BMS
p
Value
Number of patients treated 127 71 (55.9) 56 (44.1)
Total stent length, mm 25.5 11.8 27.7 11.9 21.9 10.4 0.001
Number of stents/lesion 1.1 0.3 1.2 0.4 0.9 0.6 0.001
Maximum balloon
diameter, mm
3.11 0.58 3.00 0.45 3.24 0.71 0.001
Maximum pressure
inﬂation, atm
16 4 17 4 14 4 0.30
atm atmosphere; other abbreviations as in Table 1.
Table 3. Indications for Long-Term Anticoagulation Therapy
Atrial ﬁbrillation, n (%) 75 (59.1)
Left ventricular mural thrombus, n (%) 12 (9.4)
Prosthetic valve, n (%) 15 (11.8)
Pulmonary embolism, n (%) 7 (5.5)
Deep venous thrombosis, n (%) 3 (2.4)
Coronary aneurysm, n (%) 4 (3.1)Other, n (%) 3 (2.4)
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59The MACCE and bleeding complications that occurred
uring clinical follow-up are summarized in Table 4.
Five patients (3.9%) died (5.6% in the DES group vs.
.8% in the BMS group; p  0.39) during follow up. Four
f them died in the DES group; 3 died of major bleeding
hile on triple therapy (2 in the DES group, 1 in the BMS
roup). The detailed characteristics of the patients and
auses of death are described in Table 5.
Overall, only 1 patient had a definite stent thrombosis. The
vent occurred 1 month after the index procedure after acetyl-
alicylic acid and warfarin discontinuation, owing to severe
astrointestinal hemorrhage requiring blood transfusion.
While on triple therapy, 6 (4.7%) patients developed
ajor bleeding: 3 (50%) of them died, and the remaining 4
xperienced severe comorbidities (Table 6). Most of the
ajor bleeding occurred within the first month from the
ndex procedure. Minor bleeding occurred in only 3 pa-
ients, and in 2 of them within the first month (Table 7). No
Table 4. MACCE at Follow-Up
Total
(n  127)
DES
(n  71)
BMS
(n  56) p Value
Follow-up length, months 21.0  19.8 16.9  14.0 25.5  24.0 0.021
Triple therapy length,
months
5.6  4.6 7.7  3.6 3.1  3.6 0.001
Major bleeding, n (%) 6 (4.7) 4 (5.6) 2 (3.6) 1.0
Minor bleeding, n (%) 3 (2.4) 1 (1.4) 2 (3.6) 0.57
MACCE, n (%) 30 (23.6) 14 (19.7) 16 (28.6) 0.20
Death, n (%) 5 (3.9) 4 (5.6) 1 (1.8) 0.39
MI, n (%) 2 (1.6) 1 (1.4) 1 (1.8) 1.0
CABG, n (%) 3 (2.4) 0 (0) 3 (5.4) 0.075
TVR, n (%) 25 (19.7) 10 (14.1) 15 (26.8) 0.041
TLR, n (%) 21 (16.5) 9 (12.7) 12 (21.4) 0.099
Deﬁnite stent thrombosis,
n (%)
1 (0.8) 1 (1.4) 0 (0) 1.00
AF atrial fibrillation; MACCEmajor adverse cardiac and cerebrovascular events; TLR target
lesion revascularization; TVR target vessel revascularization; other abbreviations as in Table 1.
Table 5. Characteristics of the Patients Who Died During Follow-Up
1 2
Age, yrs 83 73
CAD 3-vessel 2-vessel
EF, % 35 60
Indication for triple therapy AF AF
CHADS2 risk score 6 1
Stent type SES BMS
Description of the event Cardiocirculatory arrest
after hemodialysis
Subarachnoid hem
and death
Time from the procedure, months 2 1EF ejection fraction; PES paclitaxel-eluting stent; SES sirolimus-eluting stent; other abbreviations asignificant differences between DES and BMS were ob-
erved in the incidence of major bleeding (5.6% vs. 3.6%,
 1.0), minor bleeding (1.4% vs. 3.6%, p  0.57), and
ACCE (19.7% vs. 28.6%, p  0.20).
A significant difference in favor of DES was observed in the
ccurrence of TVR (14.1% vs. 26.8%, respectively, p 0.041).
iscussion
he main findings of this study are: 1) major bleeding occurred
n 4.7% of the patients on concomitant treatment with dual
ntiplatelet therapy and long-term AC with warfarin; 2) most
f the major bleeding complications occurred within the first
onth from the index procedure; 3) no significant difference
as observed between BMS and DES in the occurrence of
leeding complications (either major or minor), mortality, and
ACCE; and 4) a significant difference in favor of DES was
bserved in the occurrence of TVR.
The combination of aspirin and thienopyridines is the
ptimal antiplatelet therapy after PCI for the prevention of
tent thrombosis (1–4). The recommended duration of dual
ntiplatelet therapy is at least 1 month in patients receiving
MS. Current product labeling recommends dual antiplate-
et therapy for 3 months after SES and 6 months after PES
mplantation. Recently it has been recommended that after
ES implantation, dual antiplatelet therapy should be
ontinued for at least 12 months and aspirin be continued
ifelong (13). However, nearly 10% of patients referred for
CI also have clear evidence-based indications for long-
erm AC (14). Recently the ACTIVE-W (Atrial Fibrilla-
ion Clopidogrel Trial with Irbesartan for Prevention of
ascular Events) study had to be stopped early because of
he clear superiority of oral AC over dual antiplatelet
herapy in stroke prevention in patients with AF. Further-
ore, it has been largely reported that a temporary discon-
inuation of AC is associated with a higher risk of throm-
oembolism (5,15–17). At the present time, there are no
Patient #
3 4 5
72 66 74
2-vessel 2-vessel 2-vessel
30 38 50
Aortic biological prosthesis Coronary aneurysms AF
NA NA 1
SES PES SES
e Cardiac arrest 10 days after
redo aortic valve
prosthesis
Cerebral hemorrhage
and death
Cerebral hemorrhage
and death
24 2 0.5orrhagin Table 1.
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60vidence-based guidelines on the management of patients
n concomitant treatment with long-term AC and dual
ntiplatelet therapy, and thus various antithrombotic com-
inations are used in everyday practice.
In the series from Orford et al. (18) and Karjalainen et al.
14), the overall bleeding rates were 9.2% and 11.4%, respec-
ively. The incidence of major bleeding while on triple therapy
as 3.1% (18) and 6.6% (14,19). Porter et al. (20) described 2
ajor bleeding events in the population of 180 patients on
riple therapy. Buresly et al. (21) reported the incidence of
leeding events with 5 different antiplatelet and AC regimens
n 21,443 elderly (age 65 years) patients after acute MI. In
his study, the group treated with dual antiplatelet therapy
ombined with AC was very small (12 patients), and no
ignificant statistical analysis could be obtained. However, the
uthors pointed out independent predictors of bleeding: age,
erebrovascular disease, diabetes, chronic renal failure, peptic
lcer disease, and bleeding during index hospital stay. The
argest study published recently (22) reported a 5.9% incidence
f in-hospital major bleeding on triple therapy in patients (n 
80) presenting with acute coronary syndrome.
Our series represents a large group of patients (n  127) on
oncomitant treatment with dual antiplatelet therapy and AC.
n all patients the triple therapy was prescribed and continued
or 5.6  4.6 months. In some patients dual antiplatelet
herapy was prolonged (more than 1 month) after BMS
mplantation. This fact depended on the decision of the
atients’ cardiologists, who preferred to continue this thera-
Table 6. Characteristics of the Patients With Major Bleeding Complication
Patient
#
Age
(yrs) Reason for Warfarin
Type of Stent
Implanted
Thromboembolic Risk
(CHADS2 Score) T
1 66 Coronary aneurysms PES NA
2 74 AF SES 1
3 57 AF PES 5
4 73 AF BMS 0
5 75 Pulmonary embolism SES NA
6 66 AF PES 4
AF  atrial fibrillation; ASA  acetylsalicylic acid; DVT  deep vein thrombosis; Hb   hemoglobin l
Table 7. Characteristics of the Patients With Minor Bleeding Complication
Patient
#
Age
(yrs) Indication for Warfarin
Type of Stent
Implanted
Thromboe
(CHADS
1 87 AF BMS
2 68 Pulmonary embolism BMS N
3 70 AF SESAbbreviations as in Tables 1, 5, and 6.eutic regimen, especially in the cases of multivessel coronary
rtery disease in diabetic patients or in patients treated during
nstable onset of angina with percutaneous stent implantation.
espite the clinical characteristics of the patients (almost 23%
ad unstable angina, mean left ventricular ejection fraction was
4.9  13.2%, and mean age 69.9  8.8 years), no patient died
uring hospital stay and 7 (5.5%) had periprocedural MI.
oreover, none of these patients had in-hospital bleeding
omplications. At 21.0  19.8 months’ clinical follow-up, the
verall bleeding rate was 7.1% with a 4.7% incidence of major
leeding. In all patients the bleeding complication occurred
hile on concomitant treatment with dual antiplatelet therapy
nd AC. Interestingly, 50% of the patients having major
leeding died of this complication. Major bleeding events
ccurred early after the procedure.
To reduce the occurrence of bleeding events, the patients
t lower thromboembolism risk (e.g., CHADS2 2) might
e considered for temporary interruption of warfarin ther-
py and a limited period of time on double antiplatelet
herapy only. However, the exact duration of dual antiplate-
et therapy in patients necessitating warfarin, even if at low
isk of thromboembolism, cannot be clearly established on
he basis of this study.
omparison between DES and BMS. In most of the patients
55.9%), DES were implanted with a greater prevalence of
ES over PES (59.2% vs. 35.2%, respectively). The length
f triple therapy was significantly prolonged in the DES as
ompared the with BMS group (7.7 3.6 months vs. 3.1
e to Event/Triple
y Duration (Months) Event Description
2 Cerebral hemorrhage and death
0.5 Cerebral hemorrhage and death
3 Subarachnoid hemorrhage with subsequent disabling
neurological deﬁcits
1 Subarachnoid hematoma and death
1 Colon (diverticular) hemorrhage, requiring
hemotransfusion (Hb 6.4 g/dl)
1 Severe gastrointestinal hemorrhage (Hb 6.0 g/dl), requiring
hemotransfusion. ASA and warfarin interrupted
complicated by STEMI with angiographic evidence of
stent thrombosis, treated with primary PCI
er abbreviations as in Tables 1 and 5.
Risk
re)
Time to Event/Triple
Therapy Duration (Months) Event Description
1 Bleeding gastric ulcer not requiring
hemotransfusion or surgery
1 Hematuria and hemoptysis
6 Epistaxiss
Tim
heraps
mbolic
2 Sco
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61.6 months; p  0.001). Despite this, no significant
ifferences in the incidence of major bleeding (5.6% vs.
.6%), minor bleeding (1.4% vs. 3.6%,), and MACCE
19.7% vs. 28.6%) were observed between DES and BMS at
ollow-up. Conversely, a significant difference in favor of
ES was observed in the occurrence of TVR (14.1% vs.
6.8%, p  0.041). Although 4 of a total of 5 deaths
ccurred in the DES group, no significant difference was
bserved in mortality (5.6% vs. 1.8%). In addition, among
hese 4 deaths, 1 patient died after redo aortic surgery and
nother patient died owing to cerebral hemorrhage at day 15
fter stenting, when dual antiplatelet therapy would have
een required even with implantation of a BMS.
tudy limitations. This is a retrospective analysis, and thus
o “a priori” sample size has been calculated. Moreover, the
umber of patients analyzed is relatively small, mostly
ecause of the limited indication for the concomitant
reatment with dual antiplatelet and AC therapy after PCI.
o data are available on the exact INR values when bleeding
vents occurred, although we do not have any anamnesis-
ased evidence of inadequate INR control. Moreover, the
omparison between DES and BMS is probably underpow-
red because of the retrospective nature of the study and
mall sample size, and no conclusions could be drawn
egarding differences in mortality as well as safety between
he study groups.
onclusions
ur study shows that the long-term prognosis of patients
n long-term AC and dual antiplatelet therapy after PCI is
ssociated with an overall bleeding rate of 7.1%, with a 4.7%
ncidence of major bleeding. One-half of the major bleeding
omplications were fatal. The optimal strategy for treating
atients undergoing PCI with stent implantation and re-
uiring long-term AC is still unclear and will depend on
ndividual patient risk factors for thromboembolism and
leeding.
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